We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Expert Committee Supports Celltrion’s Proposed Rituxan Biosimilar
An FDA advisory committee voted in favor of licensing Celltrion’s drug candidate as a biosimilar for Roche’s blockbuster cancer-fighting Rituxan (rituximab).